- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01291602
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
August 31, 2017 updated by: Pfizer
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
This is a single and multiple dose study in healthy male and female (of non-childbearing potential) Japanese volunteers, to assess the safety, tolerability, and blood and urine drug levels of intravenous (IV) NXL104 alone and when given in combination with ceftazidime.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Glendale, California, United States
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- To be considered as 'Japanese', both of the volunteer's parents, and all grandparents must be Japanese. The volunteer must have been born in Japan, have a valid Japanese passport and must not have lived outside Japan for more than 5 years
- Have a body mass index (BMI) between 17 and 27 kg/m2 inclusive and weigh at least 45 kg and no more than 100 kg.
- Females must not be lactating, and must be of non-childbearing potential (post-menopausal at least 12 months or documented irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation
Exclusion Criteria:
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
- Symptoms of a clinically significant illness in the 3 months before the study
- History of hypersensitivity (eg, anaphylaxis), serious allergy, or any serious reaction to carbapenem, cephalosporins, or other β-lactam antibiotics
- Use within 14 days prior to the first study dose of any over-the-counter (including St. John's Wort or any herbal products) or prescription medication
- Smoker of more than 5 cigarettes/day or equivalent use of nicotine products during the previous 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NXL104
Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
|
IV Solution
|
Placebo Comparator: Placebo
Three Japanese subjects to receive placebo IV doses
|
IV saline
|
Experimental: Ceftazidime NXL104 (CAZ104)
Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
|
IV Solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events will be monitored as a measure of safety and tolerability
Time Frame: A range of 12 days
|
A range of 12 days
|
Vital signs, physical examinations, clinical laboratory tests, 12 lead electrocardiogram (ECG) and digital ECG will be assessed as a measure of safety and tolerability
Time Frame: A range of 12 days
|
A range of 12 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The pharmacokinetic parameters of plasma of NXL104 alone or in combination with ceftazidime
Time Frame: Range of 8 days
|
Range of 8 days
|
The pharmacokinetic parameters of urine of NXL104 alone or in combination with ceftazidime
Time Frame: Range of 8 days
|
Range of 8 days
|
The level of intestinal bacterial flora of NXL104 alone or in combination with ceftazidime
Time Frame: Range of 12 days
|
Range of 12 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark Yen, MD, PAREXEL Early Phase/California Clinical Trials Medical Group
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
April 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
February 6, 2011
First Submitted That Met QC Criteria
February 7, 2011
First Posted (Estimate)
February 8, 2011
Study Record Updates
Last Update Posted (Actual)
September 1, 2017
Last Update Submitted That Met QC Criteria
August 31, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D4280C00010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male and Female Japanese Volunteers
-
AstraZenecaCompletedHealthy Japanese Young and Elderly Male and Non-fertile Female VolunteersJapan
-
mAbxience Research S.L.CompletedHealthy Volunteers | Male | JapaneseJapan
-
Eisai Co., Ltd.Completed
-
AstraZenecaCompletedHealthy Japanese VolunteersUnited States
-
UCB Biopharma S.P.R.L.CompletedHealthy Japanese VolunteersUnited Kingdom
-
Astellas Pharma IncCompletedPharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male SubjectsJapan
-
VISUfarma SpACompleted
-
Clene NanomedicineCompletedHealthy Volunteers - Male and FemaleNetherlands
-
Universitätsklinikum Hamburg-EppendorfWithdrawnHealthy Male and Female VolunteersGermany
-
TakedaWithdrawn
Clinical Trials on NXL104
-
Forest LaboratoriesCompletedUrinary Tract InfectionsRussian Federation, Bulgaria, Poland, Germany, United States, Lebanon, Turkey
-
PfizerCompletedHealthyUnited Kingdom
-
PfizerCompletedComplicated Urinary Tract InfectionUnited States, Lebanon, Jordan
-
PfizerCompletedComplicated Intra-abdominal InfectionsUnited States, Lebanon, France, Romania, Bulgaria, India, Poland, Russian Federation
-
PfizerCompletedHealthy Male VolunteersUnited States